Charles Schwab Investment Management Inc Larimar Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 125,127 shares of LRMR stock, worth $452,959. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125,127
Previous 128,095
2.32%
Holding current value
$452,959
Previous $928,000
11.75%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding LRMR
# of Institutions
127Shares Held
67.3MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$76.9 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$21.9 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$20.2 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$15.4 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$15.1 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $157M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...